Faricimab is a newly approved bispecific antibody for neovascular age-related macular
degeneration (nAMD). Our study aims to evaluate clinical outcomes of faricimab switching in …

Objective To differentiate intraretinal fluid (IRF) cysts from degenerative pseudocysts in
neovascular age-related macular degeneration by quantitative multimodal imaging. Design …

The introduction of intravitreal injections of anti-vascular endothelial growth factor (VEGF)
has led to a new standard of care regarding the treatment of neovascular age-related …